PL2803662T3 - Antagonista receptora p2x4 - Google Patents
Antagonista receptora p2x4Info
- Publication number
- PL2803662T3 PL2803662T3 PL13736295T PL13736295T PL2803662T3 PL 2803662 T3 PL2803662 T3 PL 2803662T3 PL 13736295 T PL13736295 T PL 13736295T PL 13736295 T PL13736295 T PL 13736295T PL 2803662 T3 PL2803662 T3 PL 2803662T3
- Authority
- PL
- Poland
- Prior art keywords
- receptor antagonist
- antagonist
- receptor
- Prior art date
Links
- 102100037601 P2X purinoceptor 4 Human genes 0.000 title 1
- 101710189967 P2X purinoceptor 4 Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012005343 | 2012-01-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2803662T3 true PL2803662T3 (pl) | 2017-09-29 |
Family
ID=48781550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13736295T PL2803662T3 (pl) | 2012-01-13 | 2013-01-10 | Antagonista receptora p2x4 |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US9382236B2 (pl) |
| EP (1) | EP2803662B1 (pl) |
| JP (1) | JP6207399B2 (pl) |
| KR (2) | KR102092147B1 (pl) |
| CN (4) | CN111333588A (pl) |
| AU (1) | AU2013208536B2 (pl) |
| CA (1) | CA2861024C (pl) |
| DK (1) | DK2803662T3 (pl) |
| ES (1) | ES2626036T3 (pl) |
| IL (1) | IL233592B (pl) |
| NZ (1) | NZ627878A (pl) |
| PL (1) | PL2803662T3 (pl) |
| PT (1) | PT2803662T (pl) |
| SG (2) | SG10201605325TA (pl) |
| WO (1) | WO2013105608A1 (pl) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111333588A (zh) | 2012-01-13 | 2020-06-26 | 日本化学药品株式会社 | P2x4受体拮抗剂 |
| US9873683B2 (en) | 2013-07-12 | 2018-01-23 | Nippon Chemiphar Co., Ltd | P2X4 receptor antagonist |
| AU2014288115C1 (en) * | 2013-07-12 | 2018-11-15 | Kyushu University | P2X4 receptor antagonist |
| WO2015088565A1 (en) * | 2013-12-13 | 2015-06-18 | Sunovion Pharmaceuticals Inc. | P2x4 receptor modulating compounds and methods of use thereof |
| WO2016151464A1 (en) | 2015-03-24 | 2016-09-29 | Piramal Enterprises Limited | An improved process for the preparation of clobazam and its intermediate |
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| MX384836B (es) | 2016-03-07 | 2025-03-14 | Enanta Pharm Inc | Agentes antivirales contra la hepatitis b |
| AU2017255086B2 (en) * | 2016-04-28 | 2023-04-27 | Kyushu University, National University Corporation | Medicament for treatment of multiple sclerosis |
| HRP20201746T1 (hr) | 2016-05-03 | 2020-12-25 | Bayer Pharma Aktiengesellschaft | Aromatski derivati sulfonamida |
| WO2018104307A1 (en) | 2016-12-09 | 2018-06-14 | Bayer Pharma Aktiengesellschaft | Aromatic sulfonamide derivatives and their use as anatagon i sts or negative allosteric modulators of p2x4 |
| WO2018104305A1 (en) | 2016-12-09 | 2018-06-14 | Bayer Pharma Aktiengesellschaft | Field of application of the invention |
| WO2018210729A1 (en) | 2017-05-18 | 2018-11-22 | Bayer Pharma Aktiengesellschaft | Aromatic sulfonamide derivatives as antagonists or negative allosteric modulators of p2x4 receptor |
| EA202090514A1 (ru) | 2017-08-28 | 2020-06-24 | Энанта Фармасьютикалс, Инк. | Противовирусное средство против гепатита в |
| WO2019143902A2 (en) | 2018-01-22 | 2019-07-25 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| EP3766497A4 (en) * | 2018-03-14 | 2021-12-08 | Nippon Chemiphar Co., Ltd. | Drug for treating cough |
| EP3848051A4 (en) * | 2018-09-03 | 2022-06-08 | Nippon Chemiphar Co., Ltd. | DRUG TARGETING DIABETIC PERIPHERAL NEUROPATHY |
| JP2022500466A (ja) | 2018-09-21 | 2022-01-04 | エナンタ ファーマシューティカルズ インコーポレイテッド | 抗ウイルス剤としての官能化複素環 |
| SG11202105007TA (en) | 2018-11-21 | 2021-06-29 | Enanta Pharm Inc | Functionalized heterocycles as antiviral agents |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| WO2021007488A1 (en) | 2019-07-11 | 2021-01-14 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| AU2020417293A1 (en) | 2020-01-03 | 2022-09-01 | Berg Llc | Polycyclic amides as UBE2K modulators for treating cancer |
| US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| US20230149421A1 (en) * | 2020-03-30 | 2023-05-18 | Universita' Di Pisa | Medicament for preventing or treating irritable bowel syndrome or inflammatory bowel disease |
| JP2023533496A (ja) * | 2020-06-30 | 2023-08-03 | バイエル アクチェンゲゼルシャフト | 特定の眼疾患を治療するためのｐ２ｘ４受容体拮抗活性を有するｎ－フェニルアセトアミドの使用 |
| BR112022021391A2 (pt) * | 2020-06-30 | 2023-01-10 | Bayer Ag | N-fenilacetamidas substituídas que possuem atividade antagonista a receptor de p2x4 |
| US20230277552A1 (en) | 2020-08-03 | 2023-09-07 | Nippon Chemiphar Co., Ltd. | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction |
| WO2022049253A1 (en) | 2020-09-07 | 2022-03-10 | Bayer Aktiengesellschaft | Substituted n-heteroaryl-n-pyridinylacetamides as p2x4 modulators |
| PE20250155A1 (es) | 2021-06-14 | 2025-01-22 | Scorpion Therapeutics Inc | Derivados de la urea que pueden ser utilizados para tratar el cancer |
| US20250375456A1 (en) | 2021-09-30 | 2025-12-11 | Nippon Chemiphar Co., Ltd. | Agent for preventing or treating respiratory disease |
| IT202100025124A1 (it) | 2021-09-30 | 2023-03-30 | Univ Degli Studi Di Firenze | Medicamento per uso nel prevenire o trattare il dolore nocicettivo e/o viscerale |
| JP2025041993A (ja) * | 2022-02-17 | 2025-03-27 | 国立大学法人鳥取大学 | 子宮内膜症又は子宮腺筋症の予防又は治療剤 |
| CN119233829A (zh) | 2022-03-31 | 2024-12-31 | 学校法人高崎健康福祉大学 | 用于预防、抑制或治疗伴随假性过敏反应的症状的医药组合物 |
| TW202448478A (zh) | 2023-02-24 | 2024-12-16 | 日商日本化美化股份有限公司 | 具有ｐ２ｘ４受體拮抗作用之化合物的固體分散體 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5534960Y2 (pl) | 1977-01-31 | 1980-08-18 | ||
| JPS53111093A (en) * | 1977-03-07 | 1978-09-28 | Takeda Chem Ind Ltd | Imidazo(1,5-d)(1,4)benzodiazepin derivative and its preparation |
| JPH02304437A (ja) | 1989-05-19 | 1990-12-18 | Konica Corp | 新規な写真用カプラー |
| DK0756602T3 (da) | 1994-04-14 | 2000-01-31 | Glaxo Wellcome Inc | CCK- eller gastrin-modulerende 5-heterocyclo-1,5-benzodiazepiner |
| PE27497A1 (es) * | 1994-04-15 | 1997-08-07 | Glaxo Inc | Derivados de 1,5 benzodiazepina |
| SE0104250D0 (sv) | 2001-12-14 | 2001-12-14 | Astrazeneca Ab | Heterocyclic compounds |
| US20060128695A1 (en) * | 2002-10-30 | 2006-06-15 | Neuro3D | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses |
| DE10312969A1 (de) | 2003-03-24 | 2004-10-07 | Bayer Healthcare Ag | Benzofuro-1,4-diazepin-2-on-Derivate |
| US20050074819A1 (en) | 2003-10-01 | 2005-04-07 | Japan Health Sciences Foundation | Screening method of drug for treatment of neuropathic pain |
| KR100512749B1 (ko) | 2004-01-14 | 2005-09-07 | 삼성전자주식회사 | 모니터장치 |
| WO2007109182A2 (en) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| EP2058304A4 (en) | 2006-08-25 | 2012-10-10 | Nippon Chemiphar Co | P2X4 RECEPTOR ANTAGONIST |
| HRP20131113T1 (hr) | 2007-02-16 | 2014-01-17 | Merrimack Pharmaceuticals, Inc. | Protutijela protiv erbb3 i njihova uporaba |
| JP2012087053A (ja) | 2009-02-03 | 2012-05-10 | Nippon Chemiphar Co Ltd | ジアゼピンジオン誘導体 |
| CA2789641C (en) | 2009-02-16 | 2018-03-13 | Nippon Chemiphar Co., Ltd. | Diazepinedione derivative |
| CN103080094B (zh) * | 2010-07-13 | 2015-06-24 | 日本化学医药株式会社 | P2x4受体拮抗剂 |
| JP2013209292A (ja) * | 2010-07-23 | 2013-10-10 | Nippon Chemiphar Co Ltd | Ｐ２ｘ４受容体拮抗剤 |
| WO2012161301A1 (ja) | 2011-05-25 | 2012-11-29 | 国立大学法人九州大学 | ギラン・バレー症候群に伴う神経因性疼痛の予防又は治療剤 |
| CN111333588A (zh) | 2012-01-13 | 2020-06-26 | 日本化学药品株式会社 | P2x4受体拮抗剂 |
-
2013
- 2013-01-10 CN CN202010213899.0A patent/CN111333588A/zh active Pending
- 2013-01-10 CN CN201380005473.4A patent/CN104066724B/zh active Active
- 2013-01-10 SG SG10201605325TA patent/SG10201605325TA/en unknown
- 2013-01-10 PL PL13736295T patent/PL2803662T3/pl unknown
- 2013-01-10 US US14/371,868 patent/US9382236B2/en active Active
- 2013-01-10 ES ES13736295.0T patent/ES2626036T3/es active Active
- 2013-01-10 EP EP13736295.0A patent/EP2803662B1/en active Active
- 2013-01-10 AU AU2013208536A patent/AU2013208536B2/en active Active
- 2013-01-10 KR KR1020147022599A patent/KR102092147B1/ko active Active
- 2013-01-10 PT PT137362950T patent/PT2803662T/pt unknown
- 2013-01-10 JP JP2013553310A patent/JP6207399B2/ja active Active
- 2013-01-10 KR KR1020207007764A patent/KR102140746B1/ko active Active
- 2013-01-10 NZ NZ627878A patent/NZ627878A/en unknown
- 2013-01-10 DK DK13736295.0T patent/DK2803662T3/en active
- 2013-01-10 SG SG11201404030YA patent/SG11201404030YA/en unknown
- 2013-01-10 CN CN201810753396.5A patent/CN108863959B/zh active Active
- 2013-01-10 CA CA2861024A patent/CA2861024C/en active Active
- 2013-01-10 CN CN201910768337.XA patent/CN110483423A/zh active Pending
- 2013-01-10 WO PCT/JP2013/050320 patent/WO2013105608A1/ja not_active Ceased
-
2014
- 2014-07-10 IL IL233592A patent/IL233592B/en active IP Right Grant
-
2016
- 2016-06-08 US US15/176,857 patent/US9969700B2/en active Active
-
2018
- 2018-03-16 US US15/923,685 patent/US10633349B2/en active Active
-
2020
- 2020-03-23 US US16/826,877 patent/US11434207B2/en active Active
-
2022
- 2022-07-22 US US17/871,201 patent/US12116351B2/en active Active
-
2024
- 2024-08-28 US US18/817,846 patent/US20240417379A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL233592A0 (en) | p2x4 receptor antagonist | |
| GB201213700D0 (en) | Receptor antagnists II | |
| PT2927224T (pt) | Antagonistas de receptores | |
| IL238974B (en) | cxcr7 antagonists | |
| EP3020717A4 (en) | P2x4 receptor antagonist | |
| ZA201500781B (en) | 5-ht3 receptor antagonists | |
| HUE039607T2 (hu) | Progeszteron antagonisták | |
| ZA201305576B (en) | Trpm8 receptor antagonists | |
| IL232503A (en) | H2 - Indazoles as antagonists of the ep2 receptor | |
| EP2617717A4 (en) | ANTAGONIST OF P2X4 RECEIVER | |
| ZA201408172B (en) | V1a receptor agonists | |
| ZA201500220B (en) | Novel cholecystokinin receptor ligands | |
| GB201223053D0 (en) | Receptor | |
| GB2504611B (en) | Fastened Structure | |
| GB201213698D0 (en) | Receptor antagonists II | |
| GB201213699D0 (en) | Receptor antagonists II | |
| IL230334A0 (en) | Non-competitive nicotinic receptor antagonists | |
| PL2800497T3 (pl) | Unoszony oraz rozkładany mebel do siedzenia | |
| GB201210169D0 (en) | Seating |